Attovia Therapeutics, Inc.
ATTO Nasdaq
SEC CIK 2058707
Follow Attovia Therapeutics
Weekly email: filings, results
Revenue, last quarter
$0
−100% vs same quarter last year
Net income
−$22.3M
−61.6% vs same quarter last year
EPS, diluted
−$0.76
+77.9% vs same quarter last year
Operating cash flow
−$25.7M
−69.3% vs same quarter last year
Source: SEC XBRL filings · latest filing